Bristol Myers Squibb Company
https://www.bms.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bristol Myers Squibb Company
Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles
In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
Japan Q3 Roundup: Forex Impacts Majors Amid New Product Growth Expectations
Amid ongoing impact from exchange rates, Japan's five largest pharma firms showed mostly positive growth in the fiscal nine-month period. Enhertu will continue to drive Daiichi Sankyo, while Shionogi is forecasting record-breaking revenue on oral COVID-19 drug Xocova and Eisai is rolling out closely-watched Alzheimer's contender Leqembi.
Lux Capital’s Deena Shakir Bullish On Women’s Health: ‘Fundamentally A Massive Market Opportunity’
Medtech Insight talked with Lux Capital’s general partner Deena Shakir about her investments in women’s health, untapped opportunities and barriers, gender equality in investment, and her outlook for investment in women’s health.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abraxis BioScience, Inc.
- AbVitro, Inc.
- Acetylon Pharmaceuticals, Inc.
- Adnexus Therapeutics, Inc.
- Allied-Bristol Life Sciences, LLC
- Amira Pharmaceuticals, Inc.
- Amylin Pharmaceuticals, Inc.
- Avila Therapeutics, Inc.
- Bristol-Myers Company
- Bristol-Myers K.K.
- Bristol-Myers Squibb
- Cardioxyl Pharmaceuticals
- Celgene Corporation
- Cormorant Pharmaceuticals
- Delinia, Inc.
- EngMab AG
- Flexus Biosciences, Inc.
- Gloucester Pharmaceuticals, Inc.
- ißeCa Therapeutics
- IFM Therapeutics
- Impact Biomedicines, Inc.
- Inhibitex, Inc.
- iPierian Inc.
- Juno Therapeutics, Inc.
- Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
- JW Biotechnology (Shanghai) Co., Ltd
- Kosan
- Medarex, Inc.
- Padlock Therapeutics, Inc.
- Pharmion Corporation
- Quanticel Pharmaceuticals, Inc.
- Receptos, Inc.
- RedoxTherapies, Inc.
- Turning Point Therapeutics Inc.
- Westwood-Squibb Pharmaceuticals
- X-BODY, Inc.
- ZymoGenetics, Inc.
- Forbius
- MyoKardia Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice